Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 06 2023
09 06 2023
Historique:
received:
29
03
2023
accepted:
31
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
The combination of re-irradiation and bevacizumab has emerged as a potential therapeutic strategy for patients experiencing their first glioblastoma multiforme (GBM) recurrence. This study aims to assess the effectiveness of the re-irradiation and bevacizumab combination in treating second-progression GBM patients who are resistant to bevacizumab monotherapy. This retrospective study enrolled 64 patients who developed a second progression after single-agent bevacizumab therapy. The patients were divided into two groups: 35 underwent best supportive care (none-ReRT group), and 29 received bevacizumab and re-irradiation (ReRT group). The study measured the overall survival time after bevacizumab failure (OST-BF) and re-irradiation (OST-RT). Statistical tests were used to compare categorical variables, evaluate the difference in recurrence patterns between the two groups, and identify optimal cutoff points for re-irradiation volume. The results of the Kaplan-Meier survival analysis indicated that the re-irradiation (ReRT) group experienced a significantly higher survival rate and longer median survival time than the non-ReRT group. The median OST-BF and OST-RT were 14.5 months and 8.8 months, respectively, for the ReRT group, while the OST-BF for the none-ReRT group was 3.9 months (p < 0.001). The multivariable analysis identified the re-irradiation target volume as a significant factor for OST-RT. Moreover, the re-irradiation target volume exhibited excellent discriminatory ability in the area under the curve (AUC) analysis, with an optimal cutoff point of greater than 27.58 ml. These findings suggest that incorporating re-irradiation with bevacizumab therapy may be a promising treatment strategy for patients with recurrent GBM resistant to bevacizumab monotherapy. The re-irradiation target volume may serve as a valuable selection factor in determining which patients with recurrent GBM are likely to benefit from the combined re-irradiation and bevacizumab treatment modality.
Identifiants
pubmed: 37296207
doi: 10.1038/s41598-023-36290-2
pii: 10.1038/s41598-023-36290-2
pmc: PMC10256803
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9442Informations de copyright
© 2023. The Author(s).
Références
Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75
pubmed: 19169684
Am J Transl Res. 2020 Sep 15;12(9):5320-5331
pubmed: 33042422
Cancer Med. 2018 May;7(5):1742-1749
pubmed: 29573214
Lancet Oncol. 2014 Aug;15(9):943-53
pubmed: 25035291
Oncologist. 2020 Nov;25(11):e1763-e1776
pubmed: 33394574
J Clin Oncol. 2023 Feb 20;41(6):1285-1295
pubmed: 36260832
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
PLoS One. 2018 Apr 5;13(4):e0195608
pubmed: 29621341
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804
pubmed: 28870792
Neuro Oncol. 2016 Sep;18(9):1304-12
pubmed: 26951379
J Neurooncol. 2015 Oct;125(1):149-56
pubmed: 26307446
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7
pubmed: 20171513
JAMA Oncol. 2016 Nov 01;2(11):1460-1469
pubmed: 27310651
Cochrane Database Syst Rev. 2021 May 4;5:CD013579
pubmed: 34559423
Neurooncol Pract. 2017 Sep;4(3):171-181
pubmed: 31386014
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
Genomics. 2021 May;113(3):1001-1010
pubmed: 33636314
Oncologist. 2019 Apr;24(4):521-528
pubmed: 30266892
MedComm (2020). 2022 Oct 20;3(4):e182
pubmed: 36276925
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
J Neurooncol. 2016 Aug;129(1):147-54
pubmed: 27270908
Jpn J Clin Oncol. 2022 May 5;52(5):433-440
pubmed: 35079791
J Neurooncol. 2019 Mar;142(1):79-90
pubmed: 30523605
Lancet Oncol. 2019 Jan;20(1):110-119
pubmed: 30522967
Neuro Oncol. 2021 Apr 12;23(4):677-686
pubmed: 33173935
J Neurol. 2023 May;270(5):2702-2714
pubmed: 36813928
J Neurooncol. 2016 Jan;126(1):91-97
pubmed: 26369769
Front Oncol. 2020 Oct 30;10:575992
pubmed: 33215030
Radiother Oncol. 2018 Apr;127(1):121-127
pubmed: 29433917
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95
pubmed: 36196752
Br J Cancer. 2012 Oct 23;107(9):1481-7
pubmed: 23037712
Front Oncol. 2015 Apr 08;5:84
pubmed: 25905042
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Jpn J Clin Oncol. 2012 Oct;42(10):887-95
pubmed: 22844129
Radiother Oncol. 2019 Sep;138:99-105
pubmed: 31252301
Radiother Oncol. 2017 Nov;125(2):223-227
pubmed: 29054380
J Neurosurg. 2017 Jul;127(1):148-156
pubmed: 27494815
Eur J Cancer. 2023 Jan;178:13-22
pubmed: 36379185
Oncol Lett. 2017 Jul;14(1):1141-1146
pubmed: 28693286
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572958